We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

Back to rankings

81 hedge funds and large institutions have $660M invested in Audentes Therapeutics, Inc in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

61% more capital invested

Capital invested by funds: $409M → $660M (+$251M)

16% more funds holding

Funds holding: 70 → 81 (+11)

4% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 23

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
81
Holders Change
+11
Holders Change %
+15.71%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
24
Reduced
23
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$64.1M
2
AG
Artal Group
Luxembourg
+$4.34M
3
AC
Ascend Capital
California
+$3.3M
4
Morgan Stanley
Morgan Stanley
New York
+$2.88M
5
Citadel Advisors
Citadel Advisors
Florida
+$2.19M

Top Sellers

1
O
OrbiMed
New York
-$14.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.13M
3
BlackRock
BlackRock
New York
-$5.06M
4
DM
Deerfield Management
New York
-$4.43M
5
RG
Redmile Group
California
-$3.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$116M -$14.6M -672,000 -14%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$91.7M +$64.1M +2,951,598 +920%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$53.2M – – –
VVM
4
Versant Venture Management
California
$50.9M – – –
DM
5
Deerfield Management
New York
$42.7M -$4.43M -203,858 -12%
RG
6
Redmile Group
California
$36.1M -$3.7M -170,284 -12%
BlackRock
7
BlackRock
New York
$33.6M -$5.06M -232,866 -16%
Jennison Associates
8
Jennison Associates
New York
$23.6M -$48.1K -2,213 -0.3%
PA
9
Perceptive Advisors
New York
$21.9M +$1.6M +73,809 +10%
Vanguard Group
10
Vanguard Group
Pennsylvania
$21.1M +$1.63M +74,834 +11%
AllianceBernstein
11
AllianceBernstein
Tennessee
$17M -$714K -32,859 -5%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$16.2M -$512K -23,600 -4%
RSCM
13
Rock Springs Capital Management
Maryland
$14.7M -$1.52M -70,200 -12%
CC
14
Casdin Capital
New York
$11.2M – – –
Franklin Resources
15
Franklin Resources
California
$10.3M – – –
CAM
16
Cormorant Asset Management
Massachusetts
$9.06M – – –
State Street
17
State Street
Massachusetts
$7.07M +$673K +31,008 +14%
DCM
18
Driehaus Capital Management
Illinois
$6.99M -$1.17M -53,678 -18%
EAM
19
Eventide Asset Management
Massachusetts
$6.3M – – –
AG
20
Artal Group
Luxembourg
$5.6M +$4.34M +200,000 New
Northern Trust
21
Northern Trust
Illinois
$5.1M -$45.7K -2,105 -1%
OM
22
Opaleye Management
Massachusetts
$5.04M +$651K +30,000 +20%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$5.02M +$289K +13,300 +8%
AC
24
Ascend Capital
California
$4.25M +$3.3M +151,786 New
Morgan Stanley
25
Morgan Stanley
New York
$4.22M +$2.88M +132,830 +745%
1
2 3 4

BOLD Hedge Fund Activity: Q3 2017 in Review

81 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2017, worth a combined $660M — up 61% from $409M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new BOLD positions and 6 closed out — a net gain of 12 holders — while 24 added to existing stakes and 23 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $64.1M. The largest seller was OrbiMed, cutting an estimated $14.6M.

  • 81 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2017, up from 70 in Q2 2017.
  • Funds reported $660M of Audentes Therapeutics, Inc stock for Q3 2017, up 61% quarter-over-quarter.
  • 18 funds opened new Audentes Therapeutics, Inc positions in Q3 2017 and 6 closed out, a net change of +12 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q3 2017 was Fidelity Investments, an estimated $64.1M added.
  • The largest Audentes Therapeutics, Inc seller in Q3 2017 was OrbiMed, an estimated $14.6M sold.

Based on aggregated 13F filings for Q3 2017.